Inventiva(IVA) - 2023 Q2 - Earnings Call Transcript

Ed Arce - H.C. Wainwright Lucy Codrington - Jefferies & Co. Evan Wang - Guggenheim Securities Jacob Mekhael - KBC Securities So let me turn to the highlights. It's been a very busy first half, and I would say, very exciting for Inventiva. And I'll start by going over some of the key highlights regarding our key program lanifibranor, including an update on the global Phase 3 NATiV3, our Phase 2 combo study with lani and empagliflozin. And of course come back on the investigator initiated study in patients wi ...